Archive for the 'Lawrence Broxmeyer' Category

Cancer and the Science of Denial

August 11, 2017

By Dr. Lawrence Broxmeyer MD

Broxmeyer L. Cancer and the Science of Denial. J Tumor Med Prev 2017;1(3):1-26

Cancer and the Science of Denial. From: J OF TUMOR MED & PREV 1(3): 555563

  • Lawrence  Broxmeyer, MD
    Uploaded by
    L. Broxmeyer, MD

Submitted: May 24, 2017  Published: July 14, 2017

Abstract
The word ‘cancer’ is of Latin derivation and means crab. By the turn of the 20th Century organized medicine had come to the conclusion that it was not a matter of whether infectious disease caused cancer, but which one. Then, in 1910, certain American medical powers did a 180-degree rotation –abruptly deciding that cancer was not caused by a microbe. This flew in the face of over two hundred years of research in which a cancer germ had been discovered and rediscovered. Of all the infectious possibilities for cancer, unquestionably the one class of microbes that has been long recognized to most consistently mimic and imitate ‘cancer’ at both clinical and tissue levels were the mycobacteria of the family Actinomycetales of which tuberculosis and leprosy are premier examples. The association of TB with carcinoma was initially described about 200 years ago by Bayle who considered the lung malignancy ‘cavitation cancereuse’ to merely be one of the various types of tuberculosis. Ever since, almost as if in reflex to the obvious –the potential association between TB and subsequent development of cancer has drawn active investigation.

 

References
1. Falagas ME, Kouranos VD, Athanassa Z, Kopterides P (2010) Tuberculosis and malignancy. Q J M 103(7): 461-487.
2. Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, et al. (2011) Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol 6(1): 32-37.
3. Zhang S, Guang-ling Z, Yan-sheng T (2009) Detection of Mycobacterium tuberculosis L-form infection in tissues of lung carcinoma. Chin J Public Health 25: 1317-1318.
4. Chauhan A, Madiraju MV, Fol M, Lofton H, Maloney E, et al. (2006) Mycobacterium tuberculosis Cells Growing in Macrophages Are Filamentous and Deficient in FtsZ Rings. J Bacteriol 188(5): 1856-1865.
5. World Health Organization, Global Tuberculosis Report (2016) Geneva: World Health Organization, USA.
6. Yang B, Tian Y, Cui X, Zhang W, Ma Y, et al. (2013) Detection of Mycobacterium tuberculosis L-forms and MPB64 in breast cancer tissues. The Journal of Practical Medicine 29(15): 2552-2555.
7. KJ Ryanand, CG Ray (2004) Sherris Medical Microbiology, 4th (edn), McGraw-Hill, USA.
8. Guliang H, Tefu L (1999) Mycobacterium tuberculosis L-forms. Microbial Ecology in Health and Disease 10: 129-133.
9. Kakkar S, Kapila K, Singh MK, Verma K (2000) Tuberculosis of the breast. A cytomorphologic study. Acta Cytol 44(3): 292-296.
10. Puneet, Satyendra KT, Ragini R, Sanjay Singh, Guptav SK, et al. (2005) Breast Tuberculosis: Still Common In India. The Internet Journal of Tropical Medicine 2(2).
11. Vagholkar K, Gopinathan I, Pandey S, Maurya I (2014) Tuberculosis of the Breast (Case Report and Review of Literature). The Internet Journal of Surgery 31(1).
12. Liu Y, Lin TF (1996) Studies on morphology and electron-micrographic analysis of M tuberculosis filamentous L-forms. Chinese J Micro Boil Immunobiol 16(Suppl 2): 49.
13. Dai YH, Lin TF, Huang GL (1996) A serial study on mycobacteria L-forms. Zhongguo Fanglao Zazhi 45-46.
14. Shleeva MO, Salina EG, Kaprel’iants AS (2010) Dormant form of Mycobacterium tuberculosis. Mikrobiologiia 79(1): 3-15.
15. Marcova N, Slavchev G, Michailova L (2012) Unique biological properties of Mycobacterium tuberculosis L-form variants: impact for survival under stress. Int Microbiol 15(2): 61-68.
16. Warthin AS (1899) The Coexistence of Carcinoma and Tuberculosis of the Mammary Gland. Am J M Sci 118: 25-35.
17. Rosen PP (1979) Multinucleated mammary stromal giant cells-a benign lesion that simulates invasive carcinoma. Cancer 44(4): 1305-1308.
18. Hektoen L (1898) The fate of the giant cells in healing tuberculous tissue, as observed in a case of healing tuberculous meningitis. J Exp Med 3(1): 21-52.
19. Iakimenko LN (1976) Changes in the Mitotic Regime of a Cell Culture under the Influence of Sensitins. Biull Eksp Biol Med 81(2): 237-239.
20. Golubchik IS, Iakimenko LN, Lazovskaya AL (1972) Effect of Tuberculin on the Mitotic Regime in Cell Cultures. Biull Eksp Biol Med 73(5): 105-107.
21. Rao VV, Gupta EV, Thomas IM (1990) Chromosome Damage in Untreated Tuberculosis Patients. Tubercle 71(3): 169-172.
22. Much H, Uber Die Granuläre, Nach Ziehl Nicht Färbbare Form des Tuberkulosevirus. Beit Z Klin Tuberk 8th (edn), 85(1907): 85-97.
23. Kahn MC (1929) The Developmental Cycle of the Tubercle Bacillus as Revealed by Single Cell Cultures. Am Rev Tuberc 20(1929): 150.
24. Ribbert H (1894) Beitrage zur Histogenese des Carcinoms. Arch Pathol. Anat U Physiol Virchow’s 135: 433-469.
25. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266(5192): 1865-1869.
26. Huang YQ, Li JJ, Kaplan MH, Poiesz B, Katabira E, et al. (1995) Human herpesvirus-like nucleic acid in various forms of Kaposi’s sarcoma. Lancet 345(8952): 759-761.
27. Floto RA, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, et al. (2007) Small Molecule Enhancers of Rapamycin-Induced TOR Inhibition Promote Autophagy, Reduce Toxicity in Huntington’s Disease Models and Enhance Killing of Mycobacteria by Macrophages. Autophagy 3(6): 620-622.
28. Jang WS, Kim S, Podder B, Jyoti A, Nam KW, et al. (2015) Anti-Mycobacterial Activity of Tamoxifen against Drug-Resistant and Intra-Macrophage Mycobacterium tuberculosis. J Microbiol Biotechnol 25(6): 946-950.
29. Ertem E, Yüce K, Karakartal G, Onal O, Yüce G (1990) The antituberculous effect of bleomycin. J Antimicrob Chemother 26(6): 862-863.
30. Gajadeera C, Willby MJ, Green KD, Shaul P, Fridman M, et al. (2015) Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG. J Antibiot (Tokyo) 68(3): 153-157.
31. Forbes L, Ebsworth-Mojica K, Di Done L, Li S-G, Freundlich JS, et al. (2015) A High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis. PLoS One 10(6): e0129234.
32. Subramanyam CSV, Ahuja JM, Sapra ML (1975) Miliary tuberculosis simulating acute myeloid leukemia- review of literature and report of a case. Ind J Tub 22(4): 136-141.
33. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) High throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89(5): 334-353.
34. Greenstein RJ, Su L, Shahidi A, Brown WD, Clifford A, et al. (2014) Unanticipated Mycobacterium tuberculosis complex culture inhibition by immune modulators, immune suppressants, a growth enhancer, and Vitamins A and D: clinical implications. Int J Infect Dis 26: 37-43.
35. Zhang L, Zheng Y, Callahan B, Belfort M, Liu Y (2011) Cisplatin Inhibits Protein Splicing, Suggesting Inteins as Therapeutic Targets in Mycobacteria. J Biol Chem 286(2): 1277-1282.
36. Batista AA, Back DF, Lang ES, Ellena J, Lemos S, et al. (2010) Palladium (II) complexes with thiosemicarbazones. Syntheses, characterization and cytotoxicity against breast cancer cells and Anti-Mycobacterium tuberculosis activity. J Braz Chem Soc 21(7): 1177-1186.
37. Datta M, Via LE, Kamoun WS, Liu C, Chen W, et al. (2015) Antivascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A 112(6): 1827-1832.
38. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, et al. (2015) Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Onco target 6(7): 4569-4584.
39. Watt B, Rayner A, Harris G (1996) Comparative activity of azithromycin against clinical isolates of mycobacteria. J Antimicrob Chemother 38(3): 539-542.
40. Walker NF, Clark SO, Oni T, Andreu N, Tezera L, et al. (2012) Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am J Respir Crit Care Med 185(9): 989-997.
41. Pang H, Li G, Wan L, Jiang Y, Liu H, et al. (2015) In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents. Int J Clin Exp Med 8(9): 15423-15431.
42. Shu X, Gao YT, Linet MS, Brinton LA, Gao RN, et al. (1987) Chloramphenicol use and childhood leukemia in Shanghai. Lancet 2(8565): 934-937.
43. Yuan ZR, Shi Y (2008) Chloramphenicol induces abnormal differentiation and inhibits apoptosis in activated T cells. Cancer Res 68(12): 4875-4881.
44. Smith RM, Joslyn DA, Gruhzit 0M, McLean IW, Penner MA, et al. (1948)Chloromycetin: biological studies. J Bacteriol 55: 425.
45. Youmans GP, Youmans AS, Osborne RR (1948) Tuberculostatic action of Chloromycetin in vitro and in vivo. Proc. Soc. Exp Biol & Med 67: 426.
46. Rattan R, Ali Fehmi R, Munkarah A (2012) Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol 2012: 928127.
47. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69(19): 7507-7511.
48. Singhal A, Jie L, Kumar P, Hong GS, Leow MK, et al. (2014) Metformin as adjunct antituberculosis therapy. Sci Transl Med 6(263): 263ra159.
49. Esumi H, Lu J, Kurashima Y, Hanaoka T (2004) Antitumor activity of pyrviniumpamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol 3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 95(8):685-690.
50. Lougheed KEA, Taylor DL, Osborne SA, Bryans JS, Buxton RS (2009) New Anti tuberculosis agents amongst known drugs Tuberculosis (Edinb) 89(5): 364-370.
51. Maitra A, Bates S, Kolvekar T, Devarajan PV, Guzman JD, et al. (2015) Repurposing -a ray of hope in tackling extensively drug resistance in tuberculosis. Int J Infect Dse 32: 50-55.
52. Livingston (1972) Virginia Wuerthele-Caspe. Cancer: a new breakthrough, Nash Publishing, Los Angeles, USA.
53. Ewing J (1919) Neoplastic diseases. 2nd (edn), WB Saunders, Philadelphia, USA, p. 1027.
54. Rusch HP (1985) The beginnings of cancer research centers in the United States. J Natl Cancer Inst 74(2): 391-403.
55. Hunter D (1978) The diseases of occupation. 6th (edn), Little Brown and Company, Boston, UK.
56. Fraenkel E, Much H (1910) Uber die Hodgkinsche Krankheit (Lymphomatosis granulomatosa), insbesondere derenAtiologie. Z Hyg 67: 159-200.
57. L’Esperance E (1931) Studies in Hodgkin’s disease. Annal Surg 93(1): 162-168.
58. Livingston V, Allen RM (1948) Presence of consistently recurring invasive mycobacterial forms in tumor cells. Microscop Soc Bull 2: 5-18.
59. Sweany HC (1926) Mutation forms of the tubercle bacillus. JAMA 87(15): 1206-1211.
60. Beinhauer LG, Mellon RR (1938) Pathogenesis of non-caseating epithelioid tuberculosis of hypoderm and lymph glands. Arch Dermatol Syph 37: 451-460.
61. Mellon RR, Fisher LW (1932) New studies on the filterability of pure cultures of the tubercle group of microorganisms. J Infect Dis 51(1):117-128.
62. Livingston V, Alexander-Jackson EA (1950) Cultural properties and pathogenicity of certain microorganisms observed from various proliferative and neoplastic diseases (published under Virginia Wuerthele-Caspe). Am J Med Sci 220: 636-648.
63. Boesch M (1960) The long search for the truth about cancer. GP Putnam’s Sons, New York, USA.
64. Glover T, Scott M (1926) A study of the Rous chicken sarcoma No.1. Can Lancet Practitioner 66(2): 49-62.
65. Goodman LS, Gilman A (1975) The pharmacologic basis of therapeutics. 5th (edn), MacMillan, New York, USA.
66. Skirvin JA, Relias V, Koeller J (1996) Long term sequelae of cancer chemotherapy. Highlights Oncol Practice 14(2): 26-34.
67. Pukkala E, Kyyronen P (2002) Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population based case-control study. Int J Cancer 100(3): 337-341.
68. Mankiewicz E (1965) Bacteriophages that lyse Mycobacteria andCorynebacteria and show cytopathogenic effect on tissue cultures of renal cells of Cercopithecus aethiops. Can Med Assn J 92: 31-33.
69. Dubos R (1987) The White Plague: Tuberculosis. New Brunswick, NJ: Man & Society; Rutgers University Press, USA, A Journal of History of Science 78: 615-616.
70. Aaronson JD (1926) Spontaneous tuberculosis in salt water fish. J Infect Dis 39(4): 315-320.
71. Wuerthele-Caspe VE, Alexander-Jackson E, Smith LW (1971) Some aspects of the microbiology of cancer. J Am Woman’s Med Assoc 8: 7.
72. Alexander-Jackson EA (1954) A specific type of microorganism isolated from animal and human cancer. Growth 18(1): 37-51.
73. Inoue S, Singer M (1970) Experiments on a spontaneously originated visceral tumor in the Newt Trituruspyrrhogaster. Annal NY AcadSci174(2): 729-764.
74. Lwoff A (1962) Biologic order. Karl Taylor Compton Lectures, Cambridge MA: The MIT Press, USA.
75. Klieneberger-Nobel E (1949) Origin, development and significance of L-forms in bacterial cultures. J Gen Microbiol 3: 434-442.
76. Rogers AD (1953) Erwin Frink Smith: a story of North American plant pathology. Philadelphia: American Philosophical Society 152(9): 879.
77. Seibert FB (1968) Pebbles on the Hill of a Scientist. In: Florence B (ed.), Seibert publisher, St. Petersburg, USA.
78. Cantwell A (1990) The cancer microbe. Aries Rising Press, USA.
79. Mattman LH (1993) Cell wall deficient forms-stealth pathogens. 2nd (edn), Boca Raton (ed.), CRC Press, USA.
80. Schneider B (1994) Specific binding of Bacillus Calmette-Guerinin urothelial tumor cells. In- vitro World J Urol 12(6): 337-344.
81. Rosenberg SA, Barry JM (1992) The transformed cell/unlocking the mysteries of cancer. GP Putnam’s Sons, New York, USA.
82. Devados PO, Klegerman ME, Groves MJ (1993) Phagocytosis of Mycobacterium bovis BCG organisms by murine S180 sarcoma cells. Cytobios 74(296): 49-58.
83. Moss RW (1997) The independent consumer’s guide to non-toxic treatment and prevention. Cancer therapy. Equinox Press, New York, USA.
84. Martin W (1997) Medical heroes and heretics. Old Greenwich, The Devin Adair Company, Connecticut, USA.
85. Acevedo H, Pardo M, Campbell-Acevedo E, Domingue GJ (1987) Human choriogonadotropin–like material in bacteria of different species: electron microscopy and immunocytochemical studies with monoclonal and polyclonal antibodies. J Gen Microbiol 133(3): 783-791.
86. (1990) Congress of the United States Office of Technology Assessment. Unconventional Cancer Treatments US Govt Printing Office, Washington, USA.
87. Glover TJ (1930) The bacteriology of cancer. Canada Lancet Mar 74(3): 92-111.
88. Mazet G (1941) Etude Bacteriologique sur la Maladie d’ Hodgkin. Montpellier Med, pp. 1-6.
89. Wuerthele-Caspe V (1949) Mycobacterial forms observed in tumors. J Am Med Womens Assoc 4: 135-141.
90. Alexander-Jackson E (1976) Progenitor Cryptocides, The Specific Pleomorphic Microorganism Isolated From Cancer. J Int Acad Metab 5: 31-39.
91. Alexander-Jackson E (1978) Microscopic and Submicroscopic Phases of P Cryptocides from Fresh Lymphocytic leukemia. J Int Acad Metab 1: 9-18.
92. Diller I, Diller W (1965) Intracellular acid-fast organisms isolated from malignant tissues. Trans Am Micr Soc 84: 138-148.
93. Diller I, Donnelly A, Fisher M (1967) Isolation of pleomorphic, acid- fast organisms from several strains of mice. Cancer Res 27(8): 1402-1408.
94. Seibert F, Feldmann F, Davis R, Richmond I (1970) Morphological, biological, and immunological studies on isolates from tumors and leukemic bloods. Ann N Y Acad Sci 174: 690-728.
95. Wang A, Xie J (1998) Infection of mycobacterium tuberculosis in lung cancer. Zhongguo Fei Ai ZaZhi 1(2): 92-94.
96. Xie J, Anchao W, Xiazhi Z (1999) Isolation of acid fast bacillus L- forms from carcinoma of Lung. Acta Academiae Medicinae Bengbu 24: 145-146.
97. Song LY, Yan WS, Zhao T (2002) Detection of in lung cancer tissue by indirect in situ nested PCR. Di Yi Jun Yi Da XueXueBao 22(11): 992-993.
98. Yesong WXQ, Lifa X (2004) A case report on pneumoconio tuberculosis complicated with lung cancer and Mycobacterium tuberculosis- L form infection. Chin J Industrial Med.
99. Zhang S, Guang-ling Z, Yan-sheng T (2009) Detection of Mycobacterium tuberculosis L forms infection in tissues of lung carcinoma. Chin J Public Health 25: 1317-1318.
100. Sheng TY, Kun CX, Tong H, Guang LH, Wei Z, et al. (2009) Study on the relationship between Mycobacterium tuberculosis L infection and lung cancer. Tumor 29(11): 1085-1089.
101. Tian Y, Hao T, Cao B, Zhang W, Ma Y, et al. (2015) Clinical End-Points Associated with Mycobacterium tuberculosis and Lung Cancer: Implications into Host-Pathogen Interaction and Coevolution. Bio Med Research Intern p. 9.
102. Alexander-Jackson E (1970) Ultraviolet spectrogramic microscope studies of Rous sarcoma virus cultured in cell-free medium. Ann N Y Acad Sci 174(2): 765-781.
103. Shinde SR, Chandawarkar RY, Deshmukh SP (1995) Tuberculosis of the breast masquerading as carcinoma: A study of 100 patients. World J Surg 19(3): 379-381.
104. Deng B, Huang W, Tan QY, Fan XQ, Jiang YG, et al. (2011) Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum. Mol Diagn Ther 15(1): 31-40.
105. Hatwal Deepa, Suri Vijay, Mishra Jai P, Joshi Chitra (2011) Tubercular mastitis is common in garhwal region of uttarakhand: clinico pathological features of 14 cases. Journal of Clinical and Diagnostic 5(8):1569-1573.
106. Lay G, Poquet Y, Salek-Peyron P, Puissegur MP, Botanch C, et al. (2007) Langhans giant cells from M tuberculosis-induced human granulomas cannot mediate mycobacterial uptake. J Pathol 211(1): 76-85.
107. Weiss MG, Sommerfeld J, Uplekar MW (2008) Social and cultural dimensions of gender and tuberculosis. Int J Tuberc Lung Dis 12(7):829-830.
108. Holmes CB, Hausler H, Nunn P (1998) A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 2(2): 96-104.
109. Tsuyuguchi K, Suzuki K, Matsumoto H, Tanaka E, Amitani R, et al. (2001) Effect of estrogen on Mycobacterium avium complex pulmonary infection in mice. Clin Exp Immunol 123(3): 428-434.
110. Havlik JA, Horsburgh CR, Metchock B, Williams PP, Fann SA, et al. (1992) Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 165(3):577-580.
111. Tanaka E, Amitani R, Niimi A, Suzuki K, Murayama T, et al. (1997) Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 155(6): 2041-2046.
112. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, et al. (1989) Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321(13): 863-868.
113. Reich JM, Johnson RE (1991) Mycobacterium avium complex pulmonary disease. Am Rev Respir Dis 143(6): 1381-1385.
114. Howlader N, Noone AM, Krapcho M (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda.
115. Philley JV, Kannan A, Griffith DE, Devine MS, Benwill JL, et al. (2017) Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease. Oncotarget 8(11): 18070-18081.
116. Cassidy PM, Hedberg K, Saulson A, Nelley Mc E, Winthrop KL (2009) Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 49(12): e124-e129.
117. Franson JC, Friend M (1999) Field manual of wildlife diseases, Geological Survey, Washington DC, USA.
118. Miller RE, Fowler ME (2012) Fowler’s Zoo and Wild Animal Medicine Current Therapy, Volume 7. Elsevier Health Sciences, p. 688.
119. Phillips MS, von Reyn CF (2001) Nosocomial Infections Due to Nontuberculous Mycobacteria. Clin Infect Dis 33(8): 1363-1374.
120. Nason EN (1898) The Influence of Locality on the Prevalence of Malignant Disease. Br Med J 1(1941): 679-681.
121. Jones L (1899) The Influence of Locality on the Prevalence of Cancer. Br Med J 1(1996): 812-813.
122. Mason H (1902) A Possible Predisposing Cause of Cancer. Br Med J 1(2142): 139-141.
123. Miller BA, Gloeckler Ries LA, Hankey BF (1993) SEER cancer statistics review, 1973-1990. Bethesda, MD: National Institutes of Health.
124. Kulldorff M, Feuer EJ, Miller BA, Freedman LS (1997) Breast cancer clusters in Northeastern United States: a geographic analysis. Am J Epidemiol 146(2): 161-170.
125. Jenks S (1994) Researchers to comb Long Island for potential cancer factors. J Natl Cancer Inst 86: 88-95.
126. Lewis-Michi EL, Melius JM, Kallenbach LR (1996) Breast cancer risk and residence near industry or traffic in Nassau and Suffolk counties, Long Island, New York. Arch Environ Health 51: 255-265.
127. Wittenberg C (1994) Long Island breast cancer studies move forward. J Natl Cancer Inst 86: 1501-1503.
128. Jacquez GM, Greiling DA (2003) Local clustering in breast, lung and colorectal cancer in Long Island, New York. Int J Health Geogr 2(1): 3.
129. Gammon MD, Neugut AI, Santella RM, Teitelbaum SL, Britton JA, et al. (2002) The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat 74(3): 235-254.
130. Davidson A (1999) Oxford Companion to Food. Oxford: Oxford University Press, India, p. 593.
131. Zeng Y, Du J, Pu X, Yang J, Yang T, et al. (2015) Coevolution between Cancer Activities and Food Structure of Human Being from Southwest China. Bio Med Res Int 2015:497934.
132. (2009) Long Island Duck Farm History and Ecosystem Restoration Opportunities Report. US Army Corps of Engineers, New York District. Suffolk County, NY, pp. 1-20.
133. Davids HW, Cosulich WF (1968) Water Pollution from Duck Farms and Recent Developments in Treatment. 1968. Paper presented at the June 10, 1968 meeting of the New York Water Pollution Control Association, Montauk, NY, p. 9.
134. Partridge MS, Smith WG, Rutz DA (1992) Pest and Pesticide Use Assessment for Poultry Production Systems in New York State for 1998. Pesticide Management Education Program, Cornell University, USA.
135. World Health Organization (2008) Guidelines for Drinking water Quality, Incorporating 1st and 2nd Addenda, Volume 1, Recommendations. 3rd (edn), WHO, Geneva, Switzerland.
136. Fenwick A (2006) Waterborne Diseases-Could they be Consigned to History? Science 313: 1077-1081.
137. George I, Crop P, Servais P (2001) Use of β-D-Galactosidase and β-D-Glucuronidase Activities for Quantitative Detection of Total and Faecal Coliforms in Wastewater. Can J Microbiol 47(7): 670-675.
138. Shivaprasad HL, Palmieri C (2012) Pathology of mycobacteriosis in birds. Vet Clin North Am Exot Anim Pract 15(1): 41-55.
139. Song XH, Chen HX, Zhou WS, Wang JB, Liu MF, et al. (2016) Complete Genome Sequence of Mycobacterium avium, Isolated from Commercial Domestic Pekin Ducks (Anas platyrhynchos domestica), Determined Using PacBio Single-Molecule Real-Time Technology. Genome Announc 4(5).
140. (2003) Proceedings the U.S. EPA’s Research on Microorganisms in Drinking Water Workshop August 5-7, Cincinnati, Ohio.
141. Kids Count Data Center-a project of the Annie E. Casey Foundation, Maryland, United States.
142. Rosenzweig DY (1979) Pulmonary mycobacteria infections due to Mycobacterium avium complex. Clinical features and course in 100 consecutive patients. Chest 75: 115.
143. Wolinsky E (1979) Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 119(1): 107-159.
144. Rosenzweig DY (1980) A typical mycobacteriosis. Clin Chest Med 1: 273-284.
145. Dlugovitzky D, Luchesi S (1995) Circulating immune complexes in patients with advanced tuberculosis and their association with autoantibodies and reduced CD4+ lymphocytes. Braz J Med Biol Res 28(3): 331-335.
146. Lamoureux G, Davignon L (1987) Is prior mycobacterial infection a common predisposing factor to AIDS in Haitians and Africans? Ann Inst Pasteur Immunol 138(4): 521-529.
147. Hirsch CS, Toossi Z (1999) Apoptosis and T-cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis 179(4): 945-953.
148. Chaouchi N, Arvanitakis L, Auffredou, Blanchard DA, Vazquez, et al. (1995) Characterization of transforming growth factor-B1 induced apoptosis in normal human B cells and lymphoma B cell lines. Oncogene 11(8): 1615-1622.
149. McDonald I, Wang H (1996) Transforming growth factor B1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines. Blood 87: 1147-1154.
150. Fratazzi C, Arbeit RD, Carini C, Balcewicz-Sablinska MK, Keane J, et al. (1999) Macrophage apoptosis in mycobacterial infections. J Leukoc Biol 66(5): 763-764.
151. Molloy A, Laochumroonvorapong P, Kaplan G (1994) Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J Exp Med 180(4): 1499-1509.
152. Hirsch CS, Toossi Z, Johnson JL, Luzze H, Ntambi L, et al. (2001) Augmentation of apoptosis and interferon-γ production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J of Infectious Dis 183(5): 779-788.
153. Bermudez LE, Parker A, Petrofsky M (1999) Apoptosis of Mycobacterium avium-infected macrophages is mediated by both tumour necrosis factor TNF and Fas and involves the activation of caspases. Clin Exp Immunol 116(1): 94-99.
154. Edition of the Drinking Water Standards and Health Advisories (2012) Environmental Protection Agency, Office of Water, Washington, US, pp. 1-12.
155. Shin GA, Lee J, Freeman R, Cangelosi GA (2008) Inactivation of mycobacterium avium by UV irradiation. Appl Environ Microbiol 74(22): 7067-7069.
156. Pedley S, Bartram J, Cotruvo JA, Alfred D, Gareth Rb (2004) Pathogenic
mycobacteria in water: a guide to public health consequences, monitoring and management. World Health Organization, London pp. 144-168.
157. Nalbandian A, Yan BS, Pichugin A, Bronson RT, Kramnik I (2009) Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene 28(17): 1928-1938.
158. Da Silva AL, Bresciani MJ, Karnopp TE, Weber AF, Ellwanger JH, et al. (2015) DNA damage and cellular abnormalities in tuberculosis, lung cancer and chronic obstructive pulmonary disease. Multidiscip Respir Med, pp. 10-38.
159. Daley CL, Iseman M (2012) Mycobacterium avium complex and lung cancer: chicken or egg? Both? J Thorac Oncol 7(9): 1329-1330.
160. Lande L, Peterson DD, Gogoi R, Daum G, Stampler K, et al. (2012) Association between Pulmonary Mycobacterium Avium Complex Infection and Lung Cancer. J Thorac Oncol 7(9): 1345-1351.
161. Hosoda C, Hagiwara E, Shinohara T, Baba T, Nishihira R, et al. (2014) Clinical characteristics of pulmonary Mycobacterium avium complex infection complicated with lung cancer. Kekkaku 89(8): 691-695.
162. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, et al. (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175(4): 367-416.
163. Bender F (1956) Primary pulmonary carcinoma associated with active pulmonary tuberculosis. Dis Chest 30(2): 207-216.
164. Moll A (1949) “Der Bronchialkrebs,” Medizinische Klinik. 44: 916.
165. Woodruff CE, Sen-Gupta N, Wallace S, Chapman PT, Martineau PC (1952) Anatomic Relationships between Bronchogenic Carcinoma and Calcified Nodulesin the Lung. Am Rev Tuberc 66(2): 151-160.
166. https://training.seer.cancer.gov/
167. Sunnetcioglu A, Sunnetcioglu M, Binici I, Baran AI, Karahocagil MK, et al. (2015) Comparative analysis of pulmonary and extrapulmonary tuberculosis of 411 cases. Ann Clin Microbiol Antimicrob, pp. 14-34.
168. Ates Guler S, Bozkus F, Inci MF, Kokoglu OF, Ucmak H, et al. (2015) Evaluation of pulmonary and extrapulmonary tuberculosis in immunocompetent adults: a retrospective case series analysis. Med Princ Pract 24(1): 75-79.
169. Rasolofo Razanamparany V, Ménard D, Aurégan G, Gicquel B, Chanteau S (2002) Extrapulmonary and pulmonary tuberculosis in Antananarivo (madagascar): high clustering rate in female patients. J Clin Microbiol 40(11): 3964-3969.
170. Sreeramareddy CT, Panduru KV, Verma SC, Joshi HS, Bates MN (2008)
Comparison of pulmonary and extrapulmonary tuberculosis in Nepal- a hospital-based retrospective study. BMC Infect Dis p. 8.
171. Cooper A (1829) Diseases of the Breast-Part 1. S. McDowall Publisher, London, P. 73.
172. Audebert F, Schneidewind A, Hartmann P, Kullmann F, Schölmerich J (2006) Lymph node tuberculosis as primary manifestation of Hodgkin’s disease. Med Klin (Munich) 101(6): 500-504.
173. Centkowski P, Sawczuk-Chabin J, Prochorec M, Warzocha K (2005) Hodgkin’s lymphoma and tuberculosis coexistence in cervical lymph nodes. Leuk Lymphoma 46(3): 471-475.
174. Lamden K, Watson JM, Knerer G, Ryan MJ, Jenkins PA (1996) Opportunist mycobacteria in England and Wales: 1982 to 1984. Commun Dis Rep CDR Rev 6(11): 147-51.
175. Meissner G, Anz W (1977) Sources of Mycobacterium avium complex infection resulting in human disease. Am Rev Respir Dis 116(6):1057-1064.
176. Schaad UB, Votteler TP, McCracken GH, Nelson JD (1979) Management of atypical mycobacterial lymphadenitis in childhood: a review basedon 380 cases. J Pediatr 95(3): 356-360.
177. White MP, Bangash H, Goel K, Jenkins PA (1986) Nontuberculous mycobacterial lymphadenitis. Arch Dis Child 61(4): 368-371.
178. Felini M, Johnson E, Preacely N, Sarda V, Ndetan H, et al. (2011) Apilot Case-Cohort Study of Liver and Pancreatic Cancers in Poultry Workers. Ann Epidemiol 21(10): 755-766.
179. Johnson ES, Zhou Y, Lillian Yau C, Prabhakar D, Ndetan H, et al. (2010) Mortality from malignant diseases-update of the Baltimore union poultry cohort. Cancer Causes Control 21(2): 215-221.
180. Duesberg PH (1987) Retroviruses as carcinogens and pathogens: expectations and reality. Cancer Res 47(5): 1199-1220.
181. Demochowski L, Grey CE (1957) Subcellular Structures of Possible Viral Origin in Some Mammalian Tumors. Ann NY Acad Sci, pp. 559-615.
182. Miller JM, Miller LD, Olson C, Gillette KG (1969) Virus-like particles in phytohemagglutinin-stimulated lymphocyte cultures with reference to bovine lymphosarcoma. J Natl Cancer Inst 43(6): 1297-1305.
183. Seibert FB, Yeomans F, Baker JA, Davis RL, Diller IC (1972) Bacteria in
Tumors. Trans of the NY Acad of Sci June 34(6): 504-533.
184. Buehring GC, Shen HM, Jensen HM, Choi KY, Sun D, et al. (2014) Bovine leukemia virus DNA in human breast tissue. Emerg Infect Dis 20(5): 772-782.
185. Buehring GC, Shen HM, Jensen HM, Jin DL, Hudes M, et al. (2015) Exposure to Bovine Leukemia Virus is Associated with Breast Cancer: A Case-Control Study. PLoS One 10(9): e0134304.
186. Lysenko AP, Broxmeyer L, Vlasenko VV, Krasochko PA, Lemish AP, et al. (2016) Further Evidence for Cancer as a Cell-Wall-Deficient Mycobacterial Disease. J Mol Path Epidemol 1(1): 1-12.
187. Bittner JJ (1936) Some possible effects of nursing on the mammary gland tumor incidence of mice. Science 84(2172): 162.
188. Chauveau A. Transmission of virulent diseases by the ingestion of virulent principles in the digestive tract. Gaz de Paris p. 45.
189. Klebs E (1870) On the history of tuberculosis. Virchows Arch F path Anat, p. 291.
190. Gerlach AC (1870) On the inoculability of tuberculosis and theperilla, and on the transferability of the latter by feeding. Virchows Arch F path Anat 11: 297.
191. Pfeiffer DU (1994) The role of a wildlife reservoir in the epidemiology of bovine tuberculosis. New Zealand.
192. Dameshek W, Gunz (1965) Leukemia. Am J Med Sci 249: 115.
193. Latarjet R, Duplan JF (1962) Experiment and Discussion on Leukemogenesis by Cell-Free Extracts of Radiation-Induced Leukemia in Mice. Int J Rad Biol 5(4): 339-344.
194. Dobrindt U, Reidl J (2000) Pathogenicity islands and phage conversion: evolutionary aspects of bacterial pathogenesis. Int J Med Microbiol 290: 519-527.
195. Landman OE, Burchard WK, Angelety LH (1962) Lysogeny and bacteriophage adsorption in stable and reverting L-forms of Salmonella paratyphi B and Escherichia coli. Bacteriol Proc, p. 53.
196. Nelson EL, Pickett MJ (1951) The Recovery of L Forms of Brucella and their Relation to Brucella Phage. J Infect Dis 89(3): 226-232.
197. Kruegar AP, Cohn T, Smith PN, McGuire CD (1948) Observations on the effect of penicillin on the reaction between phage and staphylococc. J Gen Physiol 31: 477-488.
198. Takahashi S (1979) L phase growth of Mycobacteria. Cell wall deficient form of Mycobacteria. Kekkaku 54: 63-70.
199. Broxmeyer L, Sosnowska D, Miltner E, Chacón O, Wagner D, et al. (2002) Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis 186(8): 1155-1160.
200. Halsted WS (1912) W.W. Duke to Halsted. In: William Stewart Halsted papers, Series I. The Alan Mason Chesney Medical Archives of the Johns Hopkins Medical Institutions, Baltimore, USA.

Advertisements

CWD Tuberculosis Found in Spongiform Disease Formerly Attributed to Prions: Its Implication towards Mad Cow Disease, Scrapie and Alzheimer’s

May 9, 2017

LINK OUT TO RESEARCH ARTICLE

Journal of MPE Molecular Pathological Epidemiology 2017 Vol. 3 No. 3: 3

Lysenko AP PhD,
Broxmeyer L MD,
Vlasenko VV PhD,
Krasochko PA PhD,
Lemish AP and
Krasnikova EL

Abstract

The TSE’S or transmissible spongiform encephalopathies, include bovine spongiform encephalopathy (also called BSE or “mad cow disease”), Creutzfeldt– Jakob disease (CJD) in humans, and “scrapie” in sheep or goats (caprine spongiform encephalopathy).  They remain a mystery, their cause still hotly debated. Current mad cow diagnosis lies solely in the detection of late appearing “prions”, an acronym for hypothesized, geneless, misfolded proteins, somehow claimed to cause the disease. Yet laboratory preparations of prions contain other things, which could include unidentified bacteria or viruses. And the only real evidence that prion originator Stanley Prusiner had in his original paper that the disease agent behind “Scrapie” in sheep and goats was devoid of DNA or RNA– was based upon the fact that he couldn’t find any. Furthermore, the rigors of prion purification alone, might, in and of themselves, have killed any causative microorganism and Heino Dringer, who did pioneer work on their nature, candidly predicts “it will turn out that the prion concept is wrong.” Roels and Walravens as well as Hartly traced Mad Cow to Mycobacterium bovis. Moreover, epidemiologic maps of the origins and peak incidence of Mad Cow in the UK, suggestively match those of England’s areas of highest bovine tuberculosis, the Southwest. The neurotaxic potential of bovine tuberculosis has for some time been well known. By 1911 Alois Alzheimer called attention to “a characteristic condition of the cortical tissue which Fischer referred to as ‘spongy cortical wasting” in Alzheimer’s disease (AD). But behind AD, Fischer suspected a microbe called Streptothrix which was constantly being mistaken and confused for tuberculosis. Our present investigation of the TSEs clearly shows cell-wall-deficient (CWD) tubercular mycobacteria present, verified by molecular analysis, ELISA, PCR and microscopy to cause spongiform encephalopathy.

Keywords: Prions; Scrapie; The Spongiform Encephalopathies; Alzheimer’s disease; The etiology of Alzheimer’s Disease; Mycobacterium tuberculosis Complex

Received: April 05, 2017; Accepted: April 27, 2017; Published: April 29, 2017

 

References

1   Curto M, Reali C, Palmieri G, Scintu F, Schivo ML, et al. (2004) Inhibition of Cytokines Expression in Human Microglia Infected with Virulent  and  Nonvirulent  Mycobacteria.  Neurochem  Internat  44: 381-392.

2    Broxmeyer  L,  Sosnowska  D,  Miltner  E,  Chacón  O,  Wagner  D,  et al. (2002) Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis 186: 1155-1160.

3    Randall PJ, Hsu NJ, Lang D, Cooper S, Sebesho B, et al. (2014) Neurons are host cells for Mycobacterium tuberculosis. Infect Immun 82: 1880-1890.

4    Manuelidis  EE,  Manuelidis  L  (1989)  Suggested  Links  Between Different Types of Dementias: Creutzfeldt-Jakob disease, Alzheimer disease, and Retroviral CNS Infections. Alzheimer Dis Assoc Disord 3: 100-109.

5    Stockman S (1911) The habits of British ticks found on sheep and cattle. J Comp Pathol 24: 229-37.

6    Fischer O (1911) The spongious loss of the bones, a special process of destruction of the cerebral cortex. Z ges Neurol Psychiat 7: 1-33.

7   Babes V, Levaditi C (1897) On the Actinomycotic Shape of the Tuberculosis Bacilli (Sur la Forme Actinomycosique du Bacilli de la Tuberculosis). Arch of Med Exp et D’anat 9: 1041-1048.

8    Dunkin GW (1936) Paratuberculosis of Cattle and Sheep. Section of Comparative Medicine. Proc R Soc Med 30: 83-90

9    Chauveau A: Transmission of virulent diseases by the ingestion of virulent principles in the digestive tract. Gaz de Paris: p 45.

10  Klebs E (1870) On the history of tuberculosis. Virchows Arch F path Anat :p 291

11  Gerlach  AC  (1870)  On  the  inoculability  of  tuberculosis  and  the perilla, and on the transferability of the latter by feeding. Virchows Arch F path Anat 11: 297.

12  Pfeiffer DU (1994) The role of a wildlife reservoir in the epidemiology of bovine tuberculosis. Massey University, Dept of Veterinary Clinical Sciences, New Zealand.

13 Bourne J, Donnelly C (2001) An epidemiological investigation into bovine tuberculosis third report of the Independent Scientific Group on Cattle TB.

14  Francis  J  (1947)  Bovine  Tuberculosis:  Including  a  Contrast  with Human Tuberculosis. Staples Press Limited, London: p 220.

15  Taubes G (1986) The game of the name is fame. But is it science? Discover 7: 28-52.

16 Hadlow WJ, Prusiner SB, Kennedy RC, Race RE (1980) Brain tissue from persons dying of Creutzfeldt-Jacob disease causes scrapie-like encephalopathy in goats. Ann Neurol 8: 628-631.

17  Griffith JS (1967) Self-replication and scrapie. Nature 215: 1043-4.

18  Prusiner SB (1995) The  prion  diseases. Sci Am 272: 48-51.

19  Pethe K, Bifani P, Drobecq H, Sergheraert C, Debrie AS, et al. (2002) Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc Natl Acad Sci USA 2002 99: 10759-10764.

20  Tsubuki S, Takako Y (2003) Dutch,    Flemish,    Italian    and Arctic mutations of App and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361: 1957-1958.

21  Lasmézas  CI,  Deslys  JP  (1997)  Transmission  of  the  BSE  agent to mice in the absence of detectable abnormal prion protein. Science 275: 402-405.

22  Baker  CA, Martin D, Manuelidis L (2002) Microglia from  Creutzfeld– Jakob disease-infected brains are   infectious and   show specific mRNA activation profiles. J Virol 76: 10905-10915.

23  Botsios S, Manuelidis L (2016) CJD and Scrapie Require Agent- Associated  Nucleic  Acids  for  Infection.  J  Cell  Biochem  117: 1947-1958.

24  Abalos P, Retamal P (2004) Tuberculosis: a re-emerging zoonosis? Rev Sci Tech 23: 583-94.

25  O’Reilly LM, Daborn CJ (1995) The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tuber Lung Dis 76: 1-46.

26  Grange JM (2001) Mycobacterium bovis infection in human beings. Tuberculosis 81: 71-77

27  Mattman LH (2001) Cell Wall Deficient Forms: Stealth Pathogens.CRC Press 3 (416).

28  Xalabarder C (1958) Electron microscopy of tubercle bacilli. Excerpta Medica. Sec XV Chest Dis 11: 467-473.

29  Xalabarder C (1963) The Nature of So-Called Atypical Mycobacteria. Neumol Cir Torax 24: 259-74.

30  Csillag A (1964) The mycococcus form of mycobacteria. Journ of Gen Microbio 34: 341-352

31  Shleeva  MO,  Salina  EG,  Kaprel’iants  AS  (2010)  Dormant  form  of Mycobacterium tuberculosis. Mikrobiologiia 79: 3-15

32  Zhang Y, Yang Y, Woods A, Cotter RJ, Sun Z (2001) Resuscitation of dormant Mycobacterium tuberculosis by phospholipids or specific peptides. Biochem Biophys Res Commun 284: 542-547.

33 Marcova N, Slavchev G, Michailova L (2012) Unique biological properties of Mycobacterium tuberculosis L-form variants: impact for survival under stress. Int. Microbiol 15: 61-68.

34  Shleeva MO, Mukamolova GV, Telkov MV, Berezinskaia TL, Syroeshkin AV et al. (2003) Formation of nonculturable Mycobacterium tuberculosis and their regeneration. Mikrobiologiia 72: 76-83.

35  Prusiner SB (2014) Madness and Memory: The Discovery of Prions – A New Biologic Principle of Disease. Yale University Press.

36  Hass G, Huntington R (1943) Amyloid. III The properties of amyloid deposits occurring in several species under diverse conditions. Arch Pathol 35: 226.

37 Schwartz P (1972) Amyloid degeneration and tuberculosis in the aged. Gerontologia 18: 321-362.

38 Delgado WA (1997) Amyloid deposits in labial salivary glands identified by electron microscopy. J Oral Pathol Med 26: 51-52.

39  de Beer FC, Nel AE (1984) Serum amyloid A protein and C-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis. Thorax 39: 196–200.

40  Tomiyama T, Satoshi A (1994) Rifampicin prevents the aggregation and neurotoxicity of amyloid B protein in vitro. Biochem Biophys Res Commun 204: 76-83.

41  Chauhan A, Madiraju MV, Fol M, Lofton H, Maloney E, et al. (2006) Mycobacterium  tuberculosis  Cells  Growing  in  Macrophages  Are Filamentous and Deficient in FtsZ Rings. J. Bacteriol 188: 1856-1865.

42 Markova N, Michailova L, Kussovski V, Jourdanova M (2008) Formation of Persisting Cell Wall Deficient Forms of Mycobacterium bovis BCG during Interaction with Peritoneal Macrophages in Guinea Pigs. Electronic Journal of Biology 4: 1-10

43 Thacore H, Willett HP (1966) The formation of spheroplasts of Mycobacterium tuberculosis in tissue culture cells. Am Rev Respir Dis 93: 786-796.

44 Lysenko AP, Vlasenko AP, Broxmeyer L (2014) Phenomenon of variability of mycobacteria and its use for detection of a tuberculosis infection.

45 Lysenko AP, Vlasenko VV, Broxmeyer L, Lemish AP, Novik TP, et al. (2014) The tuberculin skin test: how safe is safe?  The tuberculins contain unknown forms capable of reverting to cell-wall-deficient mycobacteria. Clinical and Experimental Medical Sciences 2: 55-73.

46  Lysenko  AP,  Broxmeyer  L,  Vlasenko  V,  Krasochko  PA,  Lemish  AP, et al. (2016) Further evidence for Cancer as Cell-wall-deficient Mycobacterial Disease. J Mol Pathol Epidemiol 1: 1-12.

47  Lysenko AP, Vlasenko VV, Lemish AP (2014) Detection of mycobacteria in tis- sues by means of the differentiating  immunoperoxidase staining. Tuberculos i bolezni legkhih. 10: 55-58.

48  Harry EJ (2001) Bacterial cell division: regulating Z-ring formation. Mol Microbiol 40: 795-803.

49  Errington J, Daniel RA, Scheffers DJ (2003) Cytokinesis in bacteria. Microbio Mol Biol Rev 67: 52-65.

50  Xalabarder C (1970) L-forms of chronic mycobacteria and nephritis. Publ Inst Antituberc(Barcelona) Supple 7:7-83.

51 Seidel B, Thomzig A, Buschmann A, Groschup MH, Peters R, et al. (2007) Scrapie agent (strain 263K) can transmit disease via the oral route after persistence in soil over years. PLoS One 2: e435.

52  Ghodbane R, Mba Medie F, Lepidi H, Nappez C, Drancourt M (2014) Long-term survival of tuberculosis complex mycobacteria in soil. Microbiology 160: 496-501.

53  Insanov AB, Gadzhiev FS (1996) Comparative Analysis of the Results of Spinal Fluid Microbiological Study in Children and Adults Who Suffered from Tuberculous Meningitis. Probl tuberk. 5: 25–28.

54  Slavchev  G,  Michailova  L,  Markova  N  (2013)  Stress-induced L-forms of M. bovis: challenge to survivability. New Microbiologica 36: 157-166.

55  Calmette A, Valtis J, Lacomme A (1928) New experimental research on tuberculous ultravirus. CR Acad Sci 186: 1778-1781.

56  Xiao X, Miravalle L, Yuan J, McGeehan J, Dong Z, et al. (2009) Failure to Detect the Presence of Prions in the Uterine and Gestational Tissues from a Gravida with Creutzfeldt – Jakob disease. Am J Pathol 174: 1602-1608.

57  Brieger EM (1949) The Host Parasite Relationship in Tuberculous Infection. Tubercle 30: 242-253.

58 Brieger EM, Glauert AM (1952) A Phase-Contrast Study of Reproduction in Mycelial Strains of Avian Tubercle Bacilli. J Gen Microbiol 7: 287-294.

59  Prusiner SB (2004) Development of the Prion Concept. Prion Biology and Diseases, Cold Spring Harbor Laboratory Press: pp 89-141.

60  Pattison IH (1988) Fifty years with scrapie: a personal reminiscence. Vet Rec 123: 661-666.

61  Pattison IH, Jones KM (1967) The possible nature of the transmissible agent of scrapie. Vet Rec 80: 7.

62  Gerston KF, Blumberg L, Tshabalala VA, Murray J (2004) Viability of mycobacteria in formalin-fixed lungs. Hum pathol 35: 571-575.

63  Vinnie DS, Mary R (2002) Does formaldehyde kill Myco tuberculosis? Tech Bull Histopath 2: 37-38.

64  Alzheimer A, Forstl H, Levy R (1991) On Certain Peculiar Diseases of Old Age. History of Psychiatry 2: 71-101.

65  Goedert M (2015) Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aß, tau and α-synuclein. Science 349: 1255555.

66 Schwab C, Hosokawa M, McGeer PL (2004) Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188: 52-64

67 Mawanda F, Wallace R (2013) Can infections cause Alzheimer’s disease? Epidemiol Rev 35: 161-80.

68  Alteri CJ, Xicahténcati-Cortes J, Hess S, Caballero-Olin G, Girón JA,et al. (2007) Mycobacterium Tuberculosis Produces Pili during Human Infection. Proc Natl Acad Sci USA 104: 5145-5150.

69 Jordal PB, Dueholm MS, Larsen P, Petersen SV, Enghild JJ, et al. (2009)  Widespread  abundance  of  functional  bacterial  amyloid in mycolata and other gram-positive bacteria. Appl Environ Microbiol 75: 4101-4110.

 

Killing of Mycobacterium avium and Mycobacterium tuberculosis by a Mycobacteriophage Delivered by a Nonvirulent Mycobacterium: A Model for Phage Therapy of Intracellular Bacterial Pathogens

January 12, 2017
Lawrence Broxmeyer, Danuta Sosnowska, Elizabeth Miltner, Ofelia Chacon, Dirk Wagner, Jeffery McGarvey, Raul G. Barletta, and Luiz E. Bermudez

Killing of Mycobacterium avium and Mycobacterium tuberculosis by a Mycobacteriophage

The Journal of Infectious Diseases

ABSTRACT

Mycobacterium avium causes disseminated infection in patients with acquired immune deficieny syndrome. Mycobacterium tuberculosis is a pathogen associated with the deaths of millions of people worldwide annually. Effective therapeutic regimens exist that are limited by the emergence of drug resistance and the inability of antibiotics to kill dormant organisms. The present study describes a system using Mycobacterium smegmatis, an avirulent mycobacterium, to deliver the lytic phage TM4 where both M. avium and M. tuberculosis reside within macrophages. These results showed that treatment of M. avium–infected, as well as M. tuberculosis –infected, RAW 264.7 macrophages, with M. smegmatis transiently infected with TM4, resulted in a significant time and titer  dependent reduction in the number of viable intracellular bacilli. In addition, the M. smegmatis vacuole harboring TM4 fuses with the M. avium vacuole in macrophages. These results suggest a potentially novel concept to kill intracellular pathogenic bacteria and warrant future development.

REFERENCES
1. Bloom B. Tuberculosis: pathogenesis, protection and control. Washington,DC: American Society for Microbiology Press, 1995.
2. Surveillance TWIGP. Anti-tuberculosis drug resistance in the world. Geneva:World Health Organization Global Tuberculosis Programme, 1997.
3. Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clin Microbiol Rev 1993; 6:266–310.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60.
5. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus–associated opportunistic infections in the United
States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000 ; 30(Suppl 1):S5–14.
6. Falkinham JO 3rd. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996; 9:177–215.
7. Guthertz LS, Damsker B, Bottone EJ, Ford EG, Midura TF, Janda JM. Mycobacterium avium and Mycobacterium intracellulare infections in patients with and without AIDS. J Infect Dis 1989; 160:1037–41.
8. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996; 40:1759–67.
9. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:1332–8.
10. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121:905–11.
11. Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium–intracellulare complex infection in patients with AIDS. Lancet 1991; 338:1107–9.
12. Bermudez LE, Kolonoski P, Young LS. Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice. Antimicrob Agents Chemother 1996; 40:1033–5.
13. Dube MP, Sattler FR, Torriani FJ, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J Infect Dis 1997; 176:1225–32.
14. Holzman D. Phage as antibacterial tool. Genetic Engineering News 1998; 18:11–16.
15. Ford ME, Stenstrom C, Hendrix RW, Hatfull GF. Mycobacteriophage TM4: genome structure and gene expression. Tuber Lung Dis 1998; 79:63–73.
16. Foley-Thomas EM, Whipple DL, Bermudez LE, Barletta RG. Phage infection,transfection and transformation of Mycobacterium avium complex and Mycobacterium paratuberculosis. Microbiology 1995; 141:1173–81.
17. Bermudez LE, Parker A, Goodman JR. Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor–independent pathway. Infect Immun 1997; 65:1916–25.
18. Jacobs WR Jr, Kalpana GV, Cirillo JD, et al. Genetic systems for mycobacteria. Methods Enzymol 1991; 204:537–55.
19. Black CM, Bermudez LE, Young LS, Remington JS. Coinfection of macrophages modulates interferon gamma and tumor necrosis factor–induced activation against intracellular pathogens. J Exp Med 1990; 172:977–80.
20. Hafner R, Inderlied CB, Peterson DM, et al. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis 1999; 180:438–47.
21. Sula L, Sulova J, Stolcpartova M. Therapy of experimental tuberculosis in guinea pigs with mycobacterial phages DS-6A, GR-21 T, My-327. Czech Med 1981; 4:209–14.
22. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35:462–70.
23. Bermudez LE, Young LS. New drugs for the therapy of mycobacterial infections. Curr Opinion Infect Dis 1995; 8:428–38.
24. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994; 263:678–81.
25. Clemens DL, Horwitz MA. Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J Exp Med 1995
; 181:257–70.
26. de Chastellier C, Lang T, Thilo L. Phagocytic processing of the macrophage endoparasite, Mycobacterium avium, in comparison to phagosomes which contain Bacillus subtilis or latex beads. Eur J Cell Biol 1995; 68:167–82.
27. Gomes MS, Paul S, Moreira AL, Appelberg R, Rabinovitch M, Kaplan G. Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages. Infect Immun 1999; 67:3199–206.

RENSE.COM: EBOLA vs African TB ― OR HOW TO HIDE A DIAGNOSIS BEHIND A FEVER

November 20, 2014

 Dr. Lawrence Broxmeyer, MD

 

The CDC has quietly lowered its “critical temperature” protocols for detecting a fever ‘characteristic’ for Ebola after one health care worker slid by with a low-grade fever ― yet tested Ebola positive ― So……
“We changed to 100.4 after the first nurse presented to hospital with symptoms of disease and her temp was not the 101.5 that Ebola patients usually present when they are having vomiting diarrhea, etcetera,” CDC spokesman Thomas Skinner told the Daily Caller.
Etcetera. Etcetera. What Skinner meant is their Ebola temperature criteria has been changed to a temperature of 100.4ºF or above.
Anyway 100.4° (or above) sounds like a nice round number. So let’s examine it.
On the National Health Service’s website, put up by the UK government, the now magically designated temperature of100.4ºF or above also appears ― but not for Ebola. They are describing temperatures characteristic for tuberculosis. (http://www.nhs.uk/Conditions/Tuberculosis/Pages/Symptoms.aspx)

And, it might be added, temperatures characteristic for a dozen-and-a-half other illnesses.
So much for the use of temperature as an Ebola criteria.

Subsequently, by October the 20th ― World Health Organization (WHO) claimed Nigeria, which used to have the highest ‘Ebola’ death rate of any country in the world (See: http://rense.com/general96/ebooraf.html – “Ebola-free” Great, but does that they can say the same about the Ebola-like symptoms originating from the African strains of tuberculosis ― namely Mycobacterium tuberculosis and Mycobacterium africanum ― still raging over there? Will they next proclaim West Africa “Tuberculosis-free?”

Extrapulmonary (outside of the lungs) tuberculosis is the most frequent cause of a prolonged Fever of Unknown Origin (FUO) and has been for a long, long time.1,2
And in patients returning from areas where tuberculosis and malaria are
Common ― such as Africa ― the index of suspicion for these diseases should be elevated.
The current question………………… is it?
REFERENCES:

1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Casademont J. Harrison’s Principles of Internal Medicine. 16th Edition. 2004. McGraw-Hill Professional Publishing. 2680 pp
2. Roth AR, Basello GM. Approach to the adult patient with fever of unknown origin.Am Fam Physician. 2003 Dec 1;68(11):2223-8.

See also:

http://www.rense.com/general96/ebotbinter.html  Ebola & African TB – An Interview With Dr. Lawrence Broxmeyer, MD Part 1  Jeff Rense Dr. Lawrence Broxmeyer, MD 11-6-14
http://www.rense.com/general96/eboaf2.html
Ebola & African TB – An Interview With Dr. Lawrence Broxmeyer, MD Part 2
http://www.rense.com/general96/ebolareal.html
Is The Ebola Virus Real? From Dr. Lawrence Broxmeyer, M.D. © U.S. Library of Congress All rights reserved 11-9-14

Vitamin C and Its Unauthorized High-Dose Use for Ebola

November 4, 2014

Dr. Lawrence Broxmeyer, MD

 

© U.S. Library of Congress. All rights reserved. November 1, 2014

 

grayscale

Vitamin C is at present untested and unapproved for treatment of the current Ebola virus outbreak. Yet its mention by many, as in past outbreaks and epidemics, is predictably being brought up. A bleeding tendency in both severe lack of Vitamin C and in Ebola is cited. Vitamin C, in moderation, is essential to our good health ― the key word being moderation. Curiously, in the current atmosphere, many believe that if Vitamin C is working to relieve a patient’s symptoms, then it must be a “virus” that it is working against ― despite repeated assurance in the literature that a “viral-like” illness does not mean a viral-caused illness. Perhaps some Vitamin C history is in order.

In 1976, two-time Nobel laureate Linus Pauling, tempered by his 1971 publication Vitamin C and the Common Cold1, published a similar sounding title ― Vitamin C. the Common Cold, and the Flu.2 And, at the same time, Pauling tossed his hat into the cancer arena by co-authoring a study regarding Vitamin C and cancer. Entitled Supplemental Ascorbate (Vitamin C) in the Supportive Treatment of Cancer, it was written with a medical doctor (Pauling was a PhD) from Scotland named Ewan Cameron.3 In the study 100 “terminal” cancer patients were treated with mega-dose 10-Grams-per-day quantities, divided throughout the day. Their results soon showed that Vitamin C helped with cancer, but not in convincing the medical establishment ― and a swirl of controversy like none he had experienced surrounded Linus Pauling.

The study, performed in Scotland, a country with an extremely high cancer rate reported that while 22% of cancer patients taking these huge doses of Vitamin C survived for more than a year after being labeled terminal ― only 0.4% of similar patients during that same time survived without the Vitamin. On average cancer patients taking the Vitamin C survived 4 times longer ― but in most cases this could be measured in days or months.

Pauling wanted the National Cancer Institute (NCI) to let him repeat the study in the US, but instead the NCI chose scientists at the Mayo Clinic. Results there under E.T. Creagan showed little going for the use of high dose Vitamin C in cancer.4 Pauling immediately objected on the grounds that most of the Mayo patients had received chemo and radiation, which weakened the very immune system needed for Vitamin C to be effective. This led to a repeat trial headed by Creagan’s second-in-command at Mayo, Charles Moertel, whose results led him again5 to denounce the use of megadose Vitamin C in advanced cancer ― even in patients with no prior chemotherapy.

This time Pauling and Cameron bounced back by saying that even this second study fell short as the vitamin was stopped prematurely if there were signs it wasn’t working. (Cameron and Pauling had continued Vitamin C indefinitely throughout their study). Also they criticized the Mayo study regarding the rebound effect that this could lead to and for not taking routine urine tests for Vitamin C prior to beginning the trial to make sure that control patients weren’t taking Vitamin C independent of the study. The controversy continued to swirl.

Actually Linus Pauling’s interest in Vitamin C grew from the research of biochemist Irwin Stone. Stone6 would eventually publish The Healing Factor: “Vitamin C” Against Disease. In the book Stone related that thru a mutation which occurred long ago man could not manufacture Vitamin C in his body.

This was a serious change, since organisms who can’t manufacture ascorbic acid (Vitamin C) were in danger of extinction. Stone placed this mutation as having occurred 55 to 65 million years ago.Ibid Scurvy, the disease resulting from too little Vitamin C could and would result.

 

 

Vitamin C

Stone’s popular book “The Healing Factor: Vitamin C Against Disease” – with a Forward from Linus Pauling, who Irwin Stone Inspired To Go On To do Vitamin C Research. Stone’s Cover Caption rightfully begins with: “Vitamin C may save your life!”

 

 

Daily Vitamin C – Necessary in Every Way

 

Stone captured that lack of Vitamin C could present as everything from a mild “not feeling right” to much, much more serious events called acute scurvy. The latter began with change of complexion (pale or muddy), loss of accustomed vigor, quick tiring, breathlessness and a desire for sleep, but progressed in severity to fleeting limb and joint pains, sore and bleeding gums, and small reddish spots (representing hemorrhaging), especially on leg hair follicles progressing at times to nosebleeds and blood in the urine. As the disease called scurvy advanced, teeth become loose and bones become so brittle that they could be broken by merely moving in bed. The body’s joints in the end became so damaged that the noise from the bones grinding upon on another could actually be heard as a rattling noise ― and death came by either sudden collapse on mild exertion or from secondary infection such as pneumonia.Ibid

 

 

Scurvy, a disease of significant Vitamin C deficiency becomes rapidly noticeable. Among its signs and symptoms are weakness, anemia, bruising, bleeding gums and loose teeth.

Scurvy, a disease of significant Vitamin C deficiency becomes rapidly noticeable. Among its signs and symptoms are weakness, anemia, bruising, bleeding gums and loose teeth.

 

 

For millennia, Stone said, man has suffered from lack of Vitamin C, and when the Hungarian Szent-Györgyi isolated it at Cambridge in 1928 and proved his findings in 1931, others were free to derive its chemical structure and produce it synthetically. Albert Szent-Györgyi came away with a Nobel Prize ― in research that began about as unexpectedly as Fleming’s find of penicillin.7

 

 

 

Chemical Formula of Vitamin C. Thanks to Szent-Gyorgyi, this Compound was Isolated and Could be Mass Produced.

Chemical Formula of Vitamin C. Thanks to Szent-Gyorgyi, this Compound was Isolated and Could be Mass Produced.

 

 

In The Healing Factor, Stone underscored that Vitamin C cannot adequately be stored. Therefore man needed to constantly replenish it through foods rich in Vitamin C. He felt the daily Vitamin C (ascorbic acid) recommended by the National Research Council of 60 mg. daily was woefully inadequate ― citing many scientists and doctors who agreed with him. Szent-Gyorgyi was among them, feeling that “the daily dosage of ascorbic acid should be much higher.”

By 1969, Stone had documented laboratory tests conducted at the National Cancer Institute which showed that ascorbic acid was lethal to certain cancer cells and harmless to normal tissue. This was all being carefully monitored by Dr. Virginia Livingston’s group at Rutgers’s ― which was at the time pulling in sizable grants from major corporations in her quest to prove that cancer was from a tubercular-like cancer germ, which stained acid-fast (as opposed to other microbes) and appeared routinely as the cause of cancer in both her laboratory animals and biopsied human tissue specimens.8

But after the discovery and isolation of Vitamin C in 1928, and the establishment of its underlying relationship to scurvy, the declining incidence of this disease has led to complacency, scurvy being thought of as a well-nigh extinct disease. All of this has resulted in failure to recognize and treat subclinical forms of this disease and its complicated relationship to other disease. Scurvy and its bleeding tendencies were caused by lack of Vitamin C of course. Why go further?

 

 

A Germ With “Particular Sensitivity” to Destruction Through Vitamin C

 

But actually the antiseptic and bacterial qualities of ascorbic acid have long been known and mycobacteria such as TB are heavily influenced by them. Moreover there began to appear laboratory proof that TB itself depleted Vitamin C levels badly and could in itself cause subclinical scurvy. According to Stone:
“The bacteria causing tuberculosis (Mycobacteria tuberculosis) is particularly sensitive to the lethal action of ascorbic acid”.Op.cit.

Two decades before its discovery and isolation, said Stone, ascorbic acid’s effect on mycobacteria such as tuberculosis began to seep into the literature empirically. As early as 1933, McConkey and Smith9 took guinea pigs fed tuberculous sputum daily and split them into two groups. The first group was subjected to a Vitamin C deficient diet, while the second group, fed two teaspoonfuls of Vitamin C rich tomato juice, completed the study. McConkey’s idea came from his clinical observation that patients hospitalized with the intestinal form of the tubercular disease, some of which were hemorrhaging, improved when tomato juice was added to their menu. In the Vitamin C deficient cohort group 26 of the animals died from intestinal ulcerations, while only 2 succumbed while taking tomato juice ― despite the small amounts (2mg) daily. This is what Stone meant when he said that TB was “particularly sensitive” to the lethal action of ascorbic acid.

McConkey’s work was confirmed by de Savitch10 ― with orange juice as the Vitamin’s source (deSavitsch et al.1934) and Birkhaug in 193811 ― both studies using what Stone felt were woefully inadequate amounts of C. Birkhaug was on to something quite important. Not only did Vitamin C protect against “the initial invasive onslaught of”Ibid progressive tubercular disease ― but the disease itself was depleting Vitamin C levels in the body.

Actually, such linkage of TB to scurvy, historically, was nothing new. No later than in 1689 did Richard Morton, one of the earliest writers on scurvy, mention in Phthisiologia, a book which gained him almost a century of fame, say:
“Scurvy is wont [accustomed] to occasion a consumption [tuberculosis] of the lungs.”12

Birkhagh though, was essentially saying that tubercular disease caused subclinical scurvy, mentioning:
“Our study has shown that by compensating for the inevitable state of hypovitaminosis [too little] C which occurs in progressive tuberculosis, we render the animal organism more resistant against the inflammatory-necrotizing effect of tuberculosis and the initial invasive onslaught of virulent tubercle bacilli.” (Birkhaug, 1938). But what Birkhaug was not picking up, according to Erwin Stone, was that that Vitamin C was drop-dead lethal to tuberculosis.

Like Birkhaugh, Andosca and Foley13 realized that tuberculosis itself created Vitamin C deficiency. Andosca: “Most authors maintain that there is a deficiency of vitamin C in tuberculous patients.” Faulkner and Taylor14, for example, disclosed an increased demand for Vitamin C with infection. Patients with tuberculosis required more than 200 mg. of ascorbic acid a day to keep the plasma level normal.

Subclinical Scurvy from TB

Bauer and Vorwerk15 found vitamin C deficiencies of from 1 to 4 grams in the tubercular, finding a direct parallel between the activity of tuberculosis and the extent of vitamin C deficiency. Borsalino16 reported a study of 140 tuberculosis patients, in which administration of vitamin C rapidly increased capillary resistance and stopped hemoptysis ― the spitting up of blood or blood-tinged sputum. However such blood loss reappeared when treatment was discontinued. By 1946, in a survey of nutrition among the northern Manitoba Indians, Moore et al17 reported a very high mortality rate from tuberculosis and pneumonia among these Canadian Indians ― which they attributed to a diet extremely low in Vitamin C.

As Irwin Stone pointed out, “There were many more reports in this sickening mass of continued repetition of ineffectual clinical tests where the investigators were correcting a nutritional deficiency instead of using ascorbic acid to actually combat the disease.”ibid In the meantime, the extent of Vitamin C deficiency or hypovitaminosis documented by Birkhaug with mycobacterial disease was soon realized to be equivalent in cancer, still another similarity in the two wasting diseases. (Carneron & Pauling, 1979)

Further positive animal studies that Vitamin C was a potent anti-tubercular were run separately by Kleimenhagen, Steinbach, and Boyden.18,19,20 culminating with Getz’s study21 of over 1000 men which intimated that were there were adequate Vitamin C blood levels ― there was no Mycobacteria tuberculosis. Still, persisted Stone: “The dogma of the vitamin theory kept these clinicians from thinking of ascorbic acid as an antibiotic and using it in the necessary antibiotic dosages.”ibid

That was until Charpy’s 1948 study22, in which a truly massive l5 Grams or 15,000 milligrams a day were given to terminal consumptive patients. These tubercular patients were so gone that one of them died before the study got underway, but the others survived and improved strikingly despite the fact that they seemed in Charpy’s words: “unaware of the enormous tuberculosis lesions they harbored”, a situation apparently again found analogous in studies of Vitamin C and cancer. Charpy does not go into possible toxicity of such high Vitamin C, nor the kidney stones that could result from it. Vitorero and Doyle23, on the other hand, found excellent results in the treatment of intestinal TB merely by injecting 500 to 600 milligrams of ascorbic acid a day initially, which was reduced to 400 milligrams as improvement was shown, and then further reduced to 200 milligrams a day. Vitorero and Doyle were quite positive about the benefits of this treatment in their few cases and recommended its use for intestinal tuberculosis.

Fast Forward to 2013

In her cancer diet, physician Virginia Livingston Op. cit used vitamins which included Vitamin C to combat her modified mycobacterial cancer germ, but not nearly to the extent of the high doses suggested by Pauling and others. But just how well Vitamin C, at the proper concentration killed even drug resistant TB had to wait until 2013.24

In an unexpected discovery, researchers at Albert Einstein College of Medicine determined that Vitamin C, all by itself, killed both TB and drug resistant TB on culture plates. The finding suggested that Vitamin C, added to existing TB drugs could enhance and possibly shorten TB therapy. The study was published in the online journal Nature Communications.

The molecular mechanism by which vitamin C exerted its lethal effect was that Vitamin C induced what is known as a Fenton reaction, causing iron to react with other molecules to create reactive oxygen species (ROS) that kill the TB (Mtb) mycobacteria.

Peculiar and Unique to TB above other microbes, Vitamin C -Through a Fenton reaction - Kills Tuberculosis (Mtb) by Causing Iron (Fe) to Create Reactive Oxygen Species (ROS) - Which Destroy Even Drug Resistant Strains of TB.

Peculiar and Unique to TB above other microbes, Vitamin C -Through a Fenton reaction – Kills Tuberculosis (Mtb) by Causing Iron (Fe) to Create Reactive Oxygen Species (ROS) – Which Destroy Even Drug Resistant Strains of TB.

What Irwin Stone had so long ago said and predicted ― that TB was “particularly sensitive” to Vitamin C ― was now recognized scientific reality.

 

REFERENCES

1. Pauling, Linus. Vitamin C and the Common Cold. Bantam Books. New York. 1971.112pp.
2. Pauling, Linus. Vitamin C, the Common Cold, and the Flu. W.H. Freeman and Company. San Francisco. 1976.230pp
3. Pauling and Cameron, 1976). Pauling, Linus and Cameron, Ewan. Supplemental Ascorbate in the Supportive Treatment of Cancer. Proceedings of the National Academy of Sciences, Vol.73: pp.3685-89. 1976.
4. Creagan ET, Moertel CG et al.Failure of high-dose vitamin C (ascorbic a N Engl J Med1979 Sep 27;301(13):687-90) therapy to benefit patients with advanced cancer. A controlled trial.
5. Moertel CG, Fleming TR, Creagan ET, Rubin J, O’Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl. J Med. 1985 Jan 17; 312(3):137-41)
6. Stone, Irwin. The Healing Factor- “Vitamin C” Against Disease. Grosset & Dunlap Publishers. New York. 1972.)
7. Kyle, R. A.; Shampo, M. A. (2000). “Albert Szent-Györgyi–Nobel laureate”. Mayo Clinic proceedings. Mayo Clinic 75 (7): 722
8. Livingston-Wheeler V, Addeo EG. The conquest of cancer. CreateSpace Independent Publishing Platform. January 30, 2013. Pp. 288.
9. McConkey, M. and D.T. Smith. The Relation of Vitamin C Deficiency to Intestinal Tuberculosis in the Guinea Pig. Journal of Experimental Medicine. Vol.58: pp. 503-12. 1933.
10. De Savitsch, et al. The Influence of Orange Juice on Experimental Tuberculosis in Guinea Pigs. National Tuberculosis Association Transactions. Vol. 30 pp. 130-135. 1934.
11. Birkhaug, K.E.. The Role of Vitamin C in the Pathogenesis of Tuberculosis in the Guinea Pig. I to V. Acta Tubeculosis Scandinavica, Vol 12: pp. 89-98, 98-104, 359-372. 1938.
12. Morton, R. Phthisiologia, seu, Exercitationes de phthisi tribus libris comprehensae totumque opus variis historiis illustratum . Latin Edition. EEBO Editions, ProQuest Publishers. (Latin) Paperback – January 3, 2011. 444pp 1689.
13. Andosca JB, Foley JA. Calcium Ribonate and Vitamin C (Nu 240-10) in the Treatment of Tuberculosis Chest.1948;14(1):107-114. p.109.
14. Faulkner J, Taylor F. Vitamin C and Infection: Ann. Int. Med.. 10:1867. 1931.
15. (Baur and Vorwerk. “Beitrag sum Vitamin C Deficit bei Lungentuberculosen.” Beitr. S. Tuberk., 91: 262, 1938)
16. Borsalino, G. “Fragilite Capillare nella Tuberculose Polmonare e le sue Modificazione par azione della vitamin C.” Gior. de clin. Med., 18: 273, 1931.
17. Moore, et al. “Nutrition among Northern Manitoba Indians.” Can. Med. Assoc. J., 54: 223, 1946.
18. Kleimenhagen, P.. Effect of Ascorbic Acid on Experimental Tuberculosis in Guinea Pigs. Zeitschrift fur Vitaminforschung. Vol 11: 209-227. 1941.
19. Steinbach, M. M. and Klein, S.J. Vitamin C in Experimental Tuberculosis in Guinea Pigs. American Review of Tuberculosis. Vol 43: 403-13. 1941.
20. (Boyden, SV, Anderson, ME. Diet and Experimental Tuberculosis in the Guinea Pig. Acta Pathologica et Microbiologica Scandinavia (Kobenhavn). Vol. 39: 107-16. 1956.
21. Getz, 1951). (Getz, HA, Henderson HJ. A Study of the Relation of Nutrition to the Development of Tuberculosis; influence of ascorbic acid and vitamin A. Am Rev Tuberc. 1951 Oct; 64(4):381–393.
22. Charpy, J., and Ascorbic Acid in Very Large Doses Alone or with Vitamin D in Tuberculosis. Bulletin de I’Academie Nationale de Medicine (Paris). Vol. 83:421-3. 1948.
23. Vitorero, JRB, Doyle, J. Treatment of intestinal tuberculosis with vitamin C, Med. Wkly., 2, 636, 1938
24. Vilchèze C, Hartman T, Weinrick B, Jacobs WR Jr. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat Commun. 2013, May;4:1881. 23 pp.

© U.S. Library of Congress
All rights reserved
November 1, 2014

SEE also: http://preview.tinyurl.com/mowcz2c